Recent years have seen the announcement of some major partnerships between big pharma and university researchers and medical centers, with companies like Pfizer Inc. and Sanofi at the forefront of developing such collaborations. While Bristol-Myers Squibb Co. also makes a priority of accessing the innovation available at the university level, it prefers to work through what it calls “micro-partnerships” that involve little or no money but also are almost free of bureaucratic red tape.
An example of this approach is a collaboration announced Feb. 28 between Bristol and the Duke Translational Medicine Institute (DTMI) at Duke University in Durham, N.C. Building on a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?